Brain-computer interface (BCI) company Precision Neuroscience has received an investment from SCI Ventures, a VC firm that claims to hold the world’s first specialist fund dedicated to addressing paralysis.
Backed by notable spinal cord injury advocates such as the Reeve Foundation, SCI’s investment into Precision will provide it with “added momentum” at what the company’s CEO, Michael Mager, views as a pivotal time for BCIs.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Precision didn’t immediately respond to Medical Device Network to confirm the investment amount received from SCI.
Mager continued in a statement: “People living with paralysis deserve solutions that are safe, effective, and practical to deliver at scale. With SCI Ventures as a partner, we’re one step closer to bringing this transformative technology to those who need it.”
Precision’s BCI, known as Layer 7 Cortical Interface, is primarily being developed to restore communication and control for people with paralysis by translating thoughts into actions, such as typing or controlling devices, and to also enable high-resolution monitoring for patients in neurocritical care. A first-in-human trial of the system was conducted in June 2023, with successful results.
The BCI rise
According to GlobalData analysts, a combination of ongoing breakthroughs and clinical trials indicate that BCIs are on the verge of commercialisation, with estimates suggesting a market launch as early as 2030.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAdding weight to this expectation, internal Neuralink documents recently reviewed by Bloomberg indicated that the company, which is helmed by billionaire entrepreneur Elon Musk, expects its Blindsight BCI to launch in 2030 and scale up to 10,000 procedures per year that are touted to bring in $500m annually.
Neuralink secured a breakthrough device designation from the US Food and Drug Administration (FDA) for Blindsight in September 2024. Currently under evaluation, the device plans to restore vision, even to those who have been blind since birth, provided their visual cortex remains intact.
While Neuralink has stolen headlines in the BCI space, due in part to its controversial founder, bold claims and huge fundraises – most recently concluding a $650m Series E funding tranche in June 2025 – innovation in the BCI space is ongoing across a range of different areas.
For instance, while Neuralink is primarily focused on restoring vision and limb movement in amputees, other companies such as Motif Neurotech and Subsense are advancing BCI’s that address cognitive and psychological conditions such as Parkinson’s and Alzheimer’s disease, and depression and anxiety.
